Trial Profile
A trial to evaluate whether lymphocytes sub-population could be related to multiple sclerosis disease reactivation at natalizumab suspension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 04 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology